Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy? | Zendy

Dario Cattaneo | Zendy; Massimo Puoti | Zendy; Salvatore Sollima | Zendy; Cristina Moioli | Zendy; Caterina UbertiFoppa | Zendy; Sara Baldelli | Zendy; Emilio Clementi | Zendy; Cristina Gervasoni | Zendy

Open Access

Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?

Author(s) -

Dario Cattaneo,

Massimo Puoti,

Salvatore Sollima,

Cristina Moioli,

Caterina UbertiFoppa,

Sara Baldelli,

Emilio Clementi,

Cristina Gervasoni

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv466

Subject(s) - raltegravir , tolerability , medicine , pharmacokinetics , therapeutic drug monitoring , pharmacology , liver transplantation , drug , nausea , gastroenterology , adverse effect , human immunodeficiency virus (hiv) , transplantation , viral load , immunology , antiretroviral therapy

Liver transplantation (LTx) is considered a safe procedure in selected HIV-infected patients. In this clinical setting raltegravir is the antiretroviral of choice due to its optimal tolerability and its negligible interactions with immunosuppressive drugs. We aimed at providing data on the pharmacokinetics of raltegravir in LTx recipients, on which the available information is inconclusive.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research